PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Meldonium→

Meldonium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
76144-81-5
Molecular formula
C6H14N2O2
Molecular weight
146.19 g/mol
Drug class
Cardiometabolic agentgamma-butyrobetaine hydroxylase and carnitine-transport modulator
Mechanism of action
Inhibits gamma-butyrobetaine hydroxylase and the OCTN2 carnitine transporter, reducing endogenous L-carnitine availability and limiting mitochondrial uptake and beta-oxidation of long-chain fatty acids. This shifts cellular energy metabolism toward glucose oxidation and may reduce oxygen consumption under ischaemic conditions.
Indications / reported uses
  • Used in selected countries as an adjunctive cardiometabolic treatment for ischaemic heart disease and related circulatory disorders; it is not approved in the United States and is not a universally authorised standard therapy.

Sources: https://pubmed.ncbi.nlm.nih.gov/26850121/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC13287051/ · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Meldonium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Meldonium Permitted Daily Exposure (PDE) report (the Meldonium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Meldonium Occupational Exposure Limit (OEL) report (the Meldonium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.